Generic Medicine Info
Indications and Dosage
Malignant blood disorders
Adult: Initially: 175-300 mg/m2 given in divided doses over 3-7 consecutive days via IV infusion over 30-60 minutes. Maintenance: 25-100 mg/m2 in a single infusion every 3-4 wk.
Pregnancy, lactation; CV disease.
Special Precautions
Myocardial irradiation and use of radiotherapy. Hepatic or renal impairment. Elderly.
Adverse Reactions
Nausea, vomiting, mucositis, irritant to tissue, sore mouth, bone-marrow suppression, hyperuricaemia. Alopoecia (rare).
Potentially Fatal: Cardiotoxicity (rare), myelosuppression in patients who received mitomycin or a nitrosourea, leucopenia.
Drug Interactions
Other cardiotoxic drugs e.g. daunorubicin or cyclophosphamide, live vaccines; decreases effects of digoxin, oral anticoagulants, phenytoin and suxamethonium.
Lab Interference
Elevated bilirubin level.
Description: Aclarubicin is an anthracycline, a cytotoxic antibiotic, and inhibits RNA synthesis through intercalation.
Distribution: Rapidly distributed into tissues after IV admin.
Metabolism: Extensively metabolised.
Excretion: Triphasic clearance. Terminal elimination half-life: About 3 hr. Excreted in urine mainly as metabolites.
MIMS Class
Cytotoxic Chemotherapy
Disclaimer: This information is independently developed by MIMS based on Aclarubicin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in